1. People's Republic of China Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
LanZhou Foci Pharmaceutical Co.,Ltd.

LanZhou Foci Pharmaceutical Co.,Ltd.

002644.SZ
LanZhou Foci Pharmaceutical Co.,Ltd.CN flagShenzhen Stock Exchange
7.18
CNY
-0.27
- -
3.67BMarket Cap
LanZhou Foci Pharmaceutical Co.,Ltd.
002644.SZ
(Shenzhen Stock Exchange)

Recent

price

7.18

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
0.79
0.81
0.6
0.66
1.11
0.69
0.71
0.98
1.07
1.23
1.31
1.6
2.04
2.28
1.92
1.79
1.4
Revenue per Share
0.15
0.1
0.07
0.07
0.1
0.09
0.12
0.15
0.14
0.14
0.21
0.18
0.21
0.13
0.12
0.1
0.09
Basic EPS, GAAP
0.1
-0.2
-0.28
-0.22
0.13
0.03
-0.41
-0.74
-0.44
-0.09
-0.12
-0.04
0.09
0.08
0.05
0.32
-0.02
Free Cash Flow per Basic Share
0.01
0.01
0.02
0.02
0.02
0.01
0.01
0.01
0.01
0.01
0.06
0.12
0.01
0.05
0.03
0.01
0.01
Dividend per Share
0.8
0.94
0.76
0.82
1.34
1.8
1.76
1.88
1.99
2.11
2.24
2.28
2.45
2.52
2.6
2.67
2.71
Book Value per Share
0.77
1.69
1.33
1.39
1.64
2.36
2.29
2.41
2.58
2.79
2.95
3.04
3.24
3.29
3.39
3.47
3.5
Tangible Book Value per Share
332
334
444
444
358
472
511
511
511
511
511
511
511
511
511
510
510
Basic Weighted Avg Shares
262
271
266
292
399
328
363
501
545
629
668
818
1,042
1,163
980
916
716
Sales/Revenue/Turnover
14.27
13.8
11.79
11.08
5.23
5.29
9.39
11.92
11.39
10.95
8.39
10.83
15.38
8.47
10.84
13.75
15.28
Operating Margin (%)
11
13
14
15
15
18
19
21
34
53
45
49
50
52
51
55
- -
Depreciation Expense
51
32
30
31
35
43
61
74
73
71
108
93
109
67
60
49
45
Net Income, GAAP
8.02
11.66
12.04
14.43
11.93
12.5
13.69
15.2
15.68
9.92
17.48
15.61
16.35
16.56
10.81
27.8
29.97
Effective Tax Rate (%)
19.53
11.82
11.4
10.5
8.68
13.11
16.77
14.78
13.39
11.31
16.17
11.41
10.42
5.78
6.13
5.37
6.21
Profit Margin (%)
111
392
335
360
455
923
1,284
727
419
552
632
660
761
771
842
892
915
Working Capital
2
2
2
- -
- -
- -
108
598
387
80
- -
1
1
1
3
8
8
LT Debt
326
648
676
703
735
1,234
1,291
1,359
1,440
1,507
1,587
1,628
1,741
1,768
1,815
1,855
1,869
Total Equity
10.08
5.95
3.73
3.52
2.33
1.53
2.25
3.02
2.75
3.57
2.82
4.52
7.79
4.64
5.35
5.08
4.02
Return on Invested Capital (%)
18.8
10.14
8.58
7.88
7.6
6.47
6.57
5.78
4.93
5.57
9.29
7.9
8.74
5.13
4.36
3.7
3.24
Return on Capital (%)
21.2
11.08
9.31
8.73
8.22
6.47
6.98
7.98
7.38
6.79
9.74
8.08
8.99
5.29
4.6
3.66
3.26
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
38
20
LT Borrowings
- -
6
6
LT Finance Leases
- -
2
2
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
511
511
Market Capitalization
4,391
4,407
4,517

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
- -
1,333
1,363
Cash, Cash Equivalents & STI
- -
524
565
Accounts Receivable, Net
- -
302
324
Inventories
- -
290
294
Total Current Liabilities
- -
441
448
Payables & Accruals
- -
- -
- -
ST Debt
- -
38
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.18%
3.19%
2.23%
Free Cash Flow
-171.3%
23.79%
543.7%
Net Income, GAAP
4.73%
-12.8%
-18.08%
Sales/Revenue/Turnover
11.84%
7.83%
-6.6%
Total Cash Common Dividend
- -
39.81%
-55.98%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
274
225
210
272
980
2025
216
213
- -
291
916
2026
212
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.04
- -
- -
- -
0.12
2025
0.04
- -
- -
- -
0.1
2026
0.04
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.03
2025
- -
- -
- -
- -
0.01
2026
- -
- -
- -
- -
- -
Similar Companies
Probiotec Limited (PBP.AX)
Can B Corp. (CANB)
Gridiron BioNutrients, Inc. (GMVP)
Atlas Energy Corp. (CANSF)
Alliance Pharma plc (APH.L)
Zhejiang Xianju Pharmaceutical Co.,Ltd. (002332.SZ)
Business
LanZhou Foci Pharmaceutical Co.,Ltd. engages primarily in the research, development, production, and sales of traditional Chinese medicines and health products. The company produces a wide range of proprietary Chinese medicines including Liuwei Dihuang Pills, Xiaoyao Pills, Erchen Pills, Incense Stomach Nourishing Pills, Angong Gyuhuang Pills, Ejiao, Fufang Huangqi Jianpi Oral Liquid, Xiangsha Yangwei Pills, Shenrong Guben Huanshao Pills, and donkey-hide gelatin, covering therapeutic categories such as tonics, cold remedies, gastrointestinal treatments, gynecology, and tranquilizing sleep aids. Additionally, it cultivates and sells Chinese herbal medicines and processes Chinese medicine tablets under brands including Min Shan and Foci. The company exports its products to over twenty-seven countries, including the United States, Canada, Japan, and several Southeast Asian and Oceanian markets. LanZhou Foci Pharmaceutical was founded in 1929 in Shanghai, relocated to Lanzhou in 1956, and is headquartered in Lanzhou New Area, Gansu Province. It is a state-owned listed company on the Shenzhen Stock Exchange since 2011. Recently, LanZhou Foci Pharmaceutical has pursued new drug research and registration projects targeting class 3.1 new drugs, planning to develop three classical traditional Chinese medicine formula preparations aimed at promoting innovation and inheritance in the industry. The company is also conducting secondary research and development on exclusive specialty products such as Shenrong Guben Shaowan, Compound Astragalus Jianpi Oral Liquid, and Shugan Xiaojidan to enhance clinical value and market competitiveness. On the corporate front, in 2023, Gansu Provincial State-owned Asset Investment Group completed a strategic acquisition of a significant stake in LanZhou Foci Pharmaceutical, reinforcing its state-backed ownership. Operationally, the company has relocated manufacturing activities to Lanzhou New Area as part of strategic industrial upgrading. Financially, the company reported mixed results for 2024 and Q1 2025, with revenue declines but gains in net income attributable to shareholders. The company continues to focus on leveraging its nearly 100-year legacy as a key traditional Chinese medicine manufacturer in northwestern China while expanding its product pipeline and enhancing market presence through innovation and state-backed investment support. These developments reflect LanZhou Foci Pharmaceutical's commitment to combining traditional medicine heritage with modern pharmaceutical research and expanding both its domestic and international footprint in the healthcare sector.